Resistance to Raf inhibition in cancer

Por Haarberg, H. Eirik, Smalley, Keiran S.M.
Publicado em 2014

Inhibition of Wee1, AKT and CDK4 underlies the efficacy of the HSP90 inhibitor XL888 in an in vivo model of NRAS mutant melanoma

Por Haarberg, H. Eirik, Paraiso, Kim H. T., Wood, Elizabeth, Rebecca, Vito W., Sondak, Vernon K., Koomen, John M., Smalley, Keiran S. M.
Publicado em 2013

Evaluating Melanoma Drug Response and Therapeutic Escape with Quantitative Proteomics

Por Rebecca, Vito W., Wood, Elizabeth, Fedorenko, Inna V., Paraiso, Kim H. T., Haarberg, H. Eirik, Chen, Yi, Xiang, Yun, Sarnaik, Amod, Gibney, Geoffrey T., Sondak, Vernon K., Koomen, John M., Smalley, Keiran S. M.
Publicado em 2014

Inhibition of HSP90 by AT13387 Delays the Emergence of Resistance to BRAF Inhibitors and Overcomes Resistance to dual BRAF and MEK Inhibition in Melanoma Models

Por Smyth, Tomoko, Paraiso, Kim H T, Hearn, Keisha, Rodriguez-Lopez, Ana M, Munck, Joanne M, Haarberg, H Eirik, Sondak, Vernon K, Thompson, Neil T, Azab, Mohammad, Lyons, John F, Smalley, Keiran S M, Wallis, Nicola G
Publicado no Mol Cancer Ther (2014)

The heat shock protein-90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms

Por Paraiso, Kim H. T., Haarberg, H. Eirik, Wood, Elizabeth, Rebecca, Vito W., Chen, Y. Ann, Xiang, Yun, Ribas, Antoni, Lo, Roger S., Weber, Jeffrey S., Sondak, Vernon K., John, Jobin K., Sarnaik, Amod A., Koomen, John M., Smalley, Keiran S. M.
Publicado em 2012